An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

NCT03845712 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Thymidine Kinase 2 Deficiency

Interventions

DRUG: doxecitine and doxribtimine

Sponsor

UCB BIOSCIENCES, Inc.